Edition:
United States

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

2.20USD
24 Mar 2017
Change (% chg)

$0.07 (+3.29%)
Prev Close
$2.13
Open
$2.14
Day's High
$2.35
Day's Low
$2.13
Volume
97,056
Avg. Vol
77,192
52-wk High
$3.05
52-wk Low
$0.49

Latest Key Developments (Source: Significant Developments)

Richard Uihlein reports 7.89 pct stake in Galectin Therapeutics
Wednesday, 18 Jan 2017 06:01pm EST 

Galectin Therapeutics Inc :Richard Uihlein reports 7.89 percent stake in Galectin Therapeutics Inc as of Dec 22 - SEC filing.  Full Article

Galectin Therapeutics Q2 loss per share $0.20
Tuesday, 9 Aug 2016 08:00am EDT 

Galectin Therapeutics Inc : Q2 loss per share $0.20 . Galectin therapeutics reports second quarter 2016 financial results and provides business update . Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S .Believes it has sufficient cash to fund currently planned operations, research and development activities through june 30, 2017.  Full Article

Galectin Therapeutics quarterly loss per share $0.20
Tuesday, 9 Aug 2016 07:51am EDT 

Galectin Therapeutics Inc : Believes it has sufficient cash to fund currently planned operations and research, development activities through June 30, 2017 . Quarterly loss per share $0.20 . Quarterly loss per share $0.20 . Top-Line data from Nash-Fx trial in Nash patients with advanced fibrosis expected to be reported by end of Sept - sec filing .Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.  Full Article

Galectin Therapeutics reports positive mid-stage data on psoriasis drug
Monday, 16 May 2016 04:05pm EDT 

Galectin Therapeutics Inc : Drug infusions were well tolerated by patients . Two adverse events were noted, one infiltration of intravenous catheter & one headache during infusion; were mild & transient .Announces Positive Interim Results From Phase 2a Trial With Gr Md-02 in moderate-to-severe plaque psoriasis.  Full Article

Galectin Therapeutics reports Q1 loss $0.24/shr
Tuesday, 10 May 2016 08:00am EDT 

Galectin Therapeutics Inc : Galectin Therapeutics reports first quarter 2016 financial results and provides business update .Q1 loss per share $0.24.  Full Article

Galectin Therapeutics Inc qtrly loss per share $0.24
Tuesday, 10 May 2016 07:56am EDT 

Galectin Therapeutics Inc : Galectin Therapeutics Inc qtrly loss per share $0.24 . Believes it has sufficient cash to fund currently planned operations, research and development activities through march 31, 2017 . Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S .Remain on track to report top-line data from 156-patient nash-cx trial in nash patients with cirrhosis by the end of 2017.  Full Article

Galectin Therapeutics Inc announces pricing of $9.8 million registered direct offering
Friday, 20 Nov 2015 09:00am EST 

Galectin Therapeutics Inc:Has entered into securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,761,900 shares of common stock at a price of $2.06 per share.Offering is expected to close on or about November 25.Net proceeds of the offering, after placement and other fees and estimated expenses payable by Galectin Therapeutics are expected to be approximately $9.1 million.  Full Article

Galectin Therapeutics Inc announces start of phase 2 clinical trial with gr-md-02
Wednesday, 16 Sep 2015 08:00am EDT 

Galectin Therapeutics Inc:Announces start of phase 2 clinical trial with gr-md-02 in nash with advanced fibrosis.Says top-line data is expected to be available in the third quarter of 2016.  Full Article

More From Around the Web

BRIEF-Galectin Therapeutics drug demonstrates clinically significant effect in eczema patients

* Galectin Therapeutics Inc - GR-MD-02 demonstrates clinically significant effect in patients with severe and refractory atopic dermatitis (eczema)